Jacobs Levy Equity Management’s Pacific Biosciences PACB Stock Holding History

Jacobs Levy Equity Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-193,469	Closed	-$667K	–	1088
2020 Q2	$667K	Buy	+193,469	New	+$659K	0.01%	741
2015 Q2	–	Sell	-27,900	Closed	-$163K	–	845
2015 Q1	$163K	Sell	27,900 -46,394	-62%	-$320K	﹤0.01%	721
2014 Q4	$582K	Sell	74,294 -36,000	-33%	-$230K	0.01%	587
2014 Q3	$542K	Sell	110,294 -33,090	-23%	-$173K	0.01%	597
2014 Q2	$886K	Sell	143,384 -59,900	-29%	-$300K	0.01%	538
2014 Q1	$1.09M	Buy	203,284 +77,694	+62%	+$491K	0.02%	521
2013 Q4	$657K	Sell	125,590 -10,400	-8%	-$47.8K	0.01%	664
2013 Q3	$751K	Buy	135,990 +42,690	+46%	+$148K	0.01%	595
2013 Q2	$236K	Buy	+93,300	New	+$232K	﹤0.01%	870

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Jacobs Levy Equity Management's PACB Position: Q3 2020 in Review

Jacobs Levy Equity Management sold out of Pacific Biosciences (PACB) in Q3 2020, closing a stake of 193,469 shares — an estimated $667K sold.

Jacobs Levy Equity Management first reported a position in PACB in Q2 2013 and held it in 9 quarters. The position peaked at $1.09M in Q1 2014. 174 funds tracked by Wall St. Rank hold PACB as of Q3 2020.

Jacobs Levy Equity Management reported no remaining Pacific Biosciences position as of Q3 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 193,469 Pacific Biosciences shares in Q3 2020, an estimated $667K.
Jacobs Levy Equity Management first reported a position in Pacific Biosciences in Q2 2013 and held it in 9 quarters.
Jacobs Levy Equity Management's Pacific Biosciences position peaked at $1.09M in Q1 2014.
174 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2020, filed 16 Nov 2020.